MedinCell S.A. (MEDCL.PA)
Develops long-acting injectable medicines for psychiatric and other diseases.
25.24-0.03%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+58.9%
The outlook
MEDCL.PA is trading near the middle of its 52-week range, currently below both its 50- and 200-day moving averages. Analysts unanimously rate it a Strong Buy with an average price target about 37% above the current level. The stock shows a bullish lean overall despite near-flat recent movement.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 9 analysts
Price trendBelow its 50- & 200-day averages
52-week range40% of the way from its 52-week low to high
Price targetAvg target +37% vs current price
Analyst price target
~12-month · 9 analysts34.51average target+36.7% vs now
Now 25.24
Low 30.00High 39.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$906.4M
52-wk high
39.68
52-wk low
15.42
50-day avg
26.83
200-day avg
26.34
Trailing P/E
—